Claim 1: a method to treat diabetes in a patient with moderate Chronic Kidney Disease of terminal stage that includes administering to the patient a compound of the formula: P - [(a) - (b)] where a is the string to insulin lispro (SEQ ID no. 1 is b)； - B Chain of insulin lispro (SEQ ID no. 2)； and P is Peg with an average Molecular Weight of approximatelyYou nearly 17.5 kDa and 40 kDa, where a and B are properly cross-linked, and P is linked by a Covalent bond to the Epsilon Amine of lysine at position 28 B. claim 5: The Method according to claim 1, wherein it is formula (1) where The average is 406 to 497.The Method of claim 7: According to any one of claims 1 to 6, wherein the rinsing of the patient's creatinine is less than 60 ml / min. claim 11: The Method according to any of claim 7, wherein the Diabetes is di ABETES Type 1.The Method of claim 12: According to any of claims 1 to 11, characterized because Diabetes is Type 2 diabetes. The Method of claim 13: According to any of claims 1 to 11, characterized because Diabetes is Type 2 diabetes.The Method of claim 14: According to any one of claims 1 to 13, the method is characterized in that the edema induced by insulin.Reivindicación 1: Un método para tratar la diabetes en un paciente teniendo la enfermedad renal de moderada a crónica de fase terminal que comprende la administración a dicho paciente de un compuesto de la fórmula: P-[(A)-(B)] donde: A es la cadena-A de insulina lispro (SEQ ID Nº 1)； B es la cadena-B de insulina lispro (SEQ ID Nº 2)； y P es PEG que tiene un peso molecular promedio de aproximadamente 17.5 kDa a cerca de 40 kDa y donde A y B son correctamente reticulados, y P es enlazado a través de un enlace covalente a la amina épsilon de la lisina en la posición 28 de B. Reivindicación 5: El método de conformidad con la reivindicación 1, caracterizado porque es de fórmula (1) donde el n promedio es de 406 a 497. Reivindicación 7: El método de conformidad con cualquiera de las reivindicaciones 1 a
